Overexpression of Her2 occurs in 15–20 % of BC patients and is associated with worse biologic behavior; that is, increased rate of metastasis, and poor clinical outcome without Her2-targeted treatment [10]. The gene discussed is ERBB2; the disease is breast cancer.